Divi’s Laboratories’ share price rose almost 15 per cent at Rs 829 in two trading sessions, as investors remain hopeful on the prospects of the company’s Unit II at Visakhapatnam, which is under inspection of the US drug regulator (USFDA). The FDA had issued an import alert in March 2017. The plant contributes almost 65 per cent to Divi’s consolidated sales (over half to US sales), and is crucial for the company’s growth. Analysts, however, caution against a premature celebration. The import alert had dealt a severe blow to the ...
TO READ THE FULL STORY, SUBSCRIBE NOW AT JUST Rs 149 A MONTH
Key stories on business-standard.com are available to premium subscribers only.
Already a premium subscriber? LOGIN NOW
LOGIN
Not a member yet ? Resister Now
Connect using any below
WHAT YOU GET
On Business Standard Digital
On
Digital
Our Partners are proud to be associated with this initiative and will contribute Rs 100 x 6 months thereafter, standard rate of Rs 149 will be charged.
Offer valid for Indian residents only
Requires you to share personal information like PAN, Date of Birth, and Income.
*Annual saving on WSJ subscription price of US$ 347.88 (12 months @ US$ 28.99 per month)
* 1US$ = 67.50 INR.
*Please note that this offer is not valid if you are/were a registered/existing user on WSJ Digital
Already registered ?